MADRID, 18 Abr. (EUROPA PRESS) -
The British laboratory GlaxoSmithKline (GSK) has reached an agreement for the acquisition of about 2,000 million dollars (1,825 million euros) of the Canadian biopharmaceutical company Bellus Health, as confirmed by the company.
Under the terms of the agreement, the outstanding Bellus shares will be acquired by GSK at a price of US$14.75 per share, implying a 103% premium to the closing price of the Canadian company's shares. in yesterday's session.
The transaction, which could be completed in the third quarter of 2023 or earlier, is subject to customary conditions, including judicial approval, approval of the acquisition by at least 66.67% of the votes cast at a meeting of shareholders of Bellus and approval by the appropriate regulatory agencies.
In this sense, the Bellus Health board of directors has unanimously recommended that the shareholders of the Canadian laboratory vote in favor of the approval of the acquisition.
According to Luke Miels, GSK's chief commercial officer, the Bellus purchase "is highly synergistic" with GSK's expertise in respiratory medicines and is expected to increase the company's adjusted earnings per share from 2027 with the potential to generate significant sales. until 2031 and beyond.